Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats

Neuropsychopharmacology

Volumn 29, Issue 8, 2004, Pages 1451-1461

  Coccurello, Roberto ^a   Breysse, Nathalie ^a   Amalric, Marianne ^a,b  

^a CNRS   (France)

^b CNRSUMR 615531   (France)

Author keywords

Adenosine A2A; MPEP; Parkinson's disease; Reaction time task

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 8 (3 CHLOROSTYRYL)CAFFEINE; ADENOSINE A2A RECEPTOR AGONIST; MAZINDOL; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; OXIDOPAMINE; PYRIDINE DERIVATIVE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; MALE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REACTION TIME;

ANIMALS; BRAIN; CAFFEINE; CONDITIONING, OPERANT; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GENE EXPRESSION REGULATION; GENES, FOS; MALE; NERVE TISSUE PROTEINS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PHOSPHOPROTEINS; PHOSPHORYLATION; PSYCHOMOTOR PERFORMANCE; PYRIDINES; RATS; REACTION TIME; RECEPTOR, ADENOSINE A2A; RECEPTORS, METABOTROPIC GLUTAMATE; SYMPATHOLYTICS;

EID: 3242765264     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300444     Document Type: Article

References (59)

1. Albin RL, Young AB, Penney JB (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375.
2. Amalric M, Baunez C, Nieoullon A (1995a). Does the blockade of excitatory amino acid transmission in the basal ganglia simply reverse reaction time deficits induced by dopamine inactivation? Behav Pharmacol 6: 508-519.
3. Amalric M, Moukhles H, Nieoullon A, Daszuta A (1995b). Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci 7: 972-980.
4. 3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl) ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther 303: 1044-1051.
5. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000). Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20: 7871-7879.
6. 2A receptor antagonist treatment of Parkinson's disease. Neurology 61: 293-296.
7. Breysse N, Amalric M, Salin P (2003). Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in Parkinsonian rats. J Neurosci 23: 8302-8309.
8. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M (2002). Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22: 5669-5678.
9. Corsi C, Melani A, Bianchi L, Pepeu G, Pedata F (1999). Effect of adenosine A2A receptor stimulation on GABA release from the striatum of young and aged rats in vivo. Neuroreport 16: 3933-3937.
10. Dawson L, Chadha A, Megalou M, Duty S (2000). The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol 129: 541-546.
11. DeLong MR (1990). Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13: 281-285.
12. 2 receptors. Neurosci Lett 324: 154-158.
13. 2 receptor-mediated modulation of contralateral rotation induced by metabotropic glutamate receptor activation. Eur J Pharmacol 287: 115-120.
14. 2A receptor antagonism potentiates L-DOPA-induced turning and c-Fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321: 143-147.
15. 5 receptors: Implications for striatal neuronal function. Proc Natl Acad Sci USA 99: 11940-11945.
16. 2 receptors in the rat striatum. Neuropharmacology 38: 129-140.
17. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A et al (1998). DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281: 838-842.
18. 2 dopamine receptors in rat striatum. Molec Brain Res 14: 186-195.
19. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51: 83-133.
20. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J (2001). Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552.
21. Gauntlett-Gilbert J, Brown VJ (1998). Reaction time deficits and Parkinson's disease. Neurosci and Biobehav Rev 22: 865-881.
22. 2A receptor antagonist in MPTP-treated monkeys. Neurology 52: 1673-1677.
23. 2A receptor antagonist. Eur J Pharmacol 406: 345-354.
24. Hauber W, Nagel J, Sauer R, Muller CE (1998). Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen. Neuroreport 9: 1803-1806.
25. 2A receptors in the caudate-putamen of rats. Eur J Neurosci 14: 1287-1293.
26. 2A receptor antagonist istradefylline in advanced Parkinson's disease. Neurology 61: 297-303.
27. 2 receptors. J Biol Chem 277: 18091-18097.
28. Jacobson KA, Nikodijevic O, Padgett WL, Gallo-Rodriguez C, Maillard M, Daly JW (1993). 8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett 323: 141-144.
29. 3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther 251: 888-893.
30. Javitch JA, Strittmatter SM, Snyder SH (1985). Differential visualization of dopamine and norepinephrine uptake sites in rat brain using 3Hmazindol autoradiography. J Neurosci 5: 1513-1521.
31. Jiang H, Jackson-Lewis V, Muthane U, Dollison A, Ferreira M, Espinosa A et al (1993). Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res 613: 347-351.
32. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43: 507-513.
33. 3H]acetylcholine release. J Neurochem 62: 960-966.
34. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Neurosci 408: 249-255.
35. Konieczny J, Ossowska K, Wolfarth S, Pilc A (1998). LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn Schmiedebergs Arch Pharmacol 358: 500-502.
36. 2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience 42: 697-703.
37. Mathiesen JM, Svendsen N, Brauner-Osborne H, Thomsen C, Ramirez MT (2003). Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138: 1026-1030.
38. 2A receptor modulation of electrically evoked endogenous GABA release from slices of globus pallidus. J of Neurochem 60: 2334-2337.
39. 2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 251: 21-25.
40. 2A receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotoxicity Res 3: 545-556.
41. 2A receptor signaling. Proc Natl Acad Sci USA 100: 1322-1327.
42. 5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41: 413-420.
43. Ouimet CC, Langley-Gullion KC, Greengard P (1998). Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudato-putamen. Brain Res 808: 8-12.
44. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates, (Edition 2) Academic Press: Sydney.
45. 1 agonists in dopamine-denervated rats. Eur J Neurosci 8: 1176-1181.
46. 2 receptors in the rat striatum. Neuropsychopharmacology 25: 505-513.
47. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ (2000). Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther 88: 427-435.
48. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 57: 1062-1067.
49. Smith Y, Charara A, Hanson JE, Paquet M, Levey AI (2000). GABA(B) and group I metabotropic glutamate receptors in the striatopallidal complex in primates. J Anat 196: 555-576.
50. Spooren WP, Gasparini F, Bergmann R, Kuhn R (2000). Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur J Pharmacol 406: 403-410.
51. 2 receptor regulation in the rat dopamine-denervated striatum. Eur J Neurosci 12: 4033-4037.
52. 2A receptors. Prog Neurobiol 59: 355-396.
53. 1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct population of striatal projection neurons. Neuroscience 84: 223-228.
54. Tallaksen-Greene SJ, Kaatz KW, Romano C, Albin RL (1998). Localization of mGluR1-like immunoreactivity and mGlur5-like immunoreactivity in identified populations of striatal neurons. Brain Res 780: 210-217.
55. Testa CM, Standaert DG, Young AB, Penney JB (1994). Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci 14: 3005-3018.
56. Walaas SI, Greengard P (1984). DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain. J Neurosci 4: 84-98.
57. Wichmann T, DeLong MR (1997). Physiology of the basal ganglia and pathophysiology of movement disorders of basal ganglia origin. In: Watts RL (eds). Movement Disorders: Neurological Principles and Practice. McGraw-Hill: New York. pp 87-97.
58. Wolfarth S, Konieczny J, Lorenc-Koci E, Ossowska K, Pilc A (2000). The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity. Amino Acids 19: 95-101.
59. 2A adenosine receptor antagonist. J Pharmacol Exp Ther 276: 398-404.